FDA Says antiepileptic drugs patients have twice the risk of suicidal behavior

Defective Drug News, Recall Information, and FDA Warnings

January 31, 2008

FDA Analysis shows patients receiving antiepileptic drugs have twice the risk of suicidal behavior.

The FDA announced today that is has completed review of reports of suicidal behavior from its clinical studies of 11 drugs used to treat epilepsy, psychiatric disorders and other conditions.

LIST OF DRUGS MENTIONED BY THE FDA:

Carbamazepine (marketed as Carbatrol, Equetro, Tegretol, Tegretol XR)

Felbamate (marketed as Felbatol)

Gabapentin (marketed as Neurontin)

Lamotrigine (marketed as Lamictal)

Levetiracetam (marketed as Keppra)

Oxcarbazepine (marketed as Trileptal)

Pregabalin (marketed as Lyrica)

Tiagabine (marketed as Gabitril)

Topiramate (marketed as Topamax)

Valproate (marketed as Depakote, Depakote ER, Depakene, Depacon)

Zonisamide (marketed as Zonegran)